iPSC来源NK细胞保持高细胞毒性并与T细胞及抗PD-1疗法协同增强体内肿瘤控制
研究开发了从诱导多能干细胞(iPSC)高效分化扩增高品质NK细胞的制造系统,所得iNK细胞可产生炎性细胞因子并对多种血液和实体肿瘤发挥强细胞毒性。iNK细胞还能招募T细胞,与T细胞及抗PD-1抗体协同进一步增强炎性因子产生和肿瘤溶解,具备「现货型」免疫治疗细胞来源的潜力。
要点
- iPSC来源NK细胞对多种血液和实体肿瘤保持强细胞毒性。
- iNK细胞可招募T细胞并与抗PD-1抗体协同增强肿瘤杀伤。
- iNK细胞制造可从单一生产获得大量剂量,具备现货型潜力。
核心结论
- iPSC来源NK细胞保持高细胞毒性,与T细胞及抗PD-1抗体协同增强体内肿瘤控制。
研究设计与样本
- 研究开发了从iPSC分化扩增高品质NK细胞的制造系统,并评估iNK细胞功能及与T细胞和抗PD-1抗体的协同作用。
主要发现
- iNK细胞产生炎性细胞因子并对多种血液和实体肿瘤发挥强细胞毒性。
- iNK细胞招募T细胞并与T细胞及抗PD-1抗体协同增强炎性细胞因子产生和肿瘤溶解。
临床怎么用
- iNK细胞可作为现货型细胞来源,与检查点抑制剂联用促进活化T细胞浸润以增强疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of immunotherapeutic monoclonal antibodies targeting checkpoint inhibitory receptors, such as programmed cell death 1 (PD-1), or their ligands, such as PD-L1, has transformed the oncology landscape. However, durable tumor regression is limited to a minority of patients. Therefore, combining immunotherapies with those targeting checkpoint inhibitory receptors is a promising strategy to bolster antitumor responses and improve response rates. Natural killer (NK) cells have the potential to augment checkpoint inhibition therapies, such as PD-L1/PD-1 blockade, because NK cells mediate both direct tumor lysis and T cell activation and recruitment. However, sourcing donor-derived NK cells for adoptive cell therapy has been limited by both cell number and quality. Thus, we developed a robust and efficient manufacturing system for the differentiation and expansion of high-quality NK cells derived from induced pluripotent stem cells (iPSCs). iPSC-derived NK (iNK) cells produced inflammatory cytokines and exerted strong cytotoxicity against an array of hematologic and solid tumors. Furthermore, we showed that iNK cells recruit T cells and cooperate with T cells and anti-PD-1 antibody, further enhancing inflammatory cytokine production and tumor lysis. Because the iNK cell derivation process uses a renewable starting material and enables the manufacturing of large numbers of doses from a single manufacture, iNK cells represent an "off-the-shelf" source of cells for immunotherapy with the capacity to target tumors and engage the adaptive arm of the immune system to make a "cold" tumor "hot" by promoting the influx of activated T cells to augment checkpoint inhibitor therapies.
引用
- Cichocki F, Bjordahl R, Gaidarova S, et al. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Sci Transl Med. 2020. PMID: 33148626. doi:10.1126/scitranslmed.aaz5618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。